BerGenBio ASA

📍 Bergen, Norway🗓 Founded 2008👥 42 employees💰 Last funded Jun 2015
Pharmaceutical Manufacturing🌐 bergenbio.com
Website LinkedIn
BerGenBio is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class selective AXL kinase inhibitors to treat multiple aggressive cancers. The Company is a world leader in understanding the central role of AXL kinase in promoting cancer spread, immune evasion and drug resistance – the cause of approximately 90 percent of cancer deaths. Inhibition of AXL kinase activity represents a novel approach to addressing a key mechanism in the evolution of cancer cell malignancy and aggressiveness, offering an opportunity to create important new therapeutic options for cancer patients.
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2008
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Denmark
1
Frequently asked questions
Who invested in BerGenBio ASA?
BerGenBio ASA has 1 investors on record on gritt.io and 1 late-stage investors.
When did BerGenBio ASA last raise funding?
The most recent investment in BerGenBio ASA recorded on gritt.io was in June 2015.
When was BerGenBio ASA founded?
BerGenBio ASA was founded in 2008.
What industry is BerGenBio ASA in?
BerGenBio ASA operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is BerGenBio ASA based?
BerGenBio ASA is headquartered in Bergen, Norway.